Summit Therapeutics GAAP EPS of -$0.28 beats by $0.01
Seeking Alpha ·
Summit Therapeutics press release ( SMMT ): Q2 GAAP EPS of -$0.28 beats by $0.01 . Aggregate cash and cash equivalents and short-term investments were $690.7 million and $713.4 million at June 30, 2026 and December 31, 2025, respectively. Summit Therapeutics: 'Buy' On Ivonescimab's November PDUFA And Impressive Partner Data Summit Therapeutics: High-Volatility, Catalyst-Driven Binary Bet Summit Therapeutics: Getting A Foot In The Door Isn't Getting Through It Summit Therapeutics Q2 2026 Earnings Preview Summit updates survival data for Akeso-partnered lung cancer drug
DYAX Investor Sentiment
Bullish (Long) 34% · Bearish (Short) 66%
347 participants
Related News
- S&T Bancorp anticipates mid-single-digit loan growth for 2026, while adding $100M buyback authorization
- Southwest projects 2026 adjusted EPS of $3.25 to $4.25 as unit revenue growth outlook remains high
- Amkor Technology, NVIDIA sign multi-year deal to boost U.S. AI chip packaging
- Bay Commercial Bank GAAP EPS of -$0.64 misses by $0.84, revenue of $25.22M beats by $0.37M
- Gold plunges as spiking oil prices lift 10-year Treasurys to 18-month high
- Isabella Bank GAAP EPS of $0.69 misses by $0.23, revenue of $22.47M misses by $0.53M
